Title. *In vivo* delayed clearance of *Plasmodium falciparum* malaria independent of *kelch13* polymorphisms and with escalating malaria in Bangladesh.

Authors. Maisha Khair Nima^{1,2}, Saiful Arefeen Sazed², Angana Mukherjee¹, Muhammad Riadul Haque Hossainey^{2,3}, Ching Swe Phru², Fatema Tuj Johora², Innocent Safeukui¹, Anjan Saha⁴ Afsana Alamgir Khan⁴, Aung Swi Prue Marma⁵, Russell E. Ware⁶, Mohandas Narla⁷, Barbara Calhoun¹, Rashidul Haque², Wasif Ali Khan², Mohammad Shafiul Alam^{2*} and Kasturi Halder^{1*}

*co-corresponding authors.

1. Boler-Paraghehian Center for Rare and Neglected Diseases, Dept. of Biological Sciences, University of Notre Dame, Notre Dame IN 46556, USA.
2. Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Mohakhali, Dhaka 1212, Bangladesh.
3. Department of Biological Sciences, George Washington University, Washington, DC 20052, USA.
4. National Malaria Elimination & Aedes Transmitted Diseases Control Program, DGHS, Mohakhali, Dhaka 1212, Bangladesh.
5. Civil Surgeon's Office, Bandarban, Bangladesh.
6. Division of Hematology, Department of Pediatrics, and the Global Health Center, Cincinnati Children's Hospital Medical Center, Cincinnati OH 45229, USA.
7. New York Blood Center, New York, NY 10065, USA.

Abstract.

The emergence of resistance to artemisinin drugs threatens global malaria control. Resistance is widely seen in South East Asia (SEA) and Myanmar, but not comprehensively assessed in Bangladesh. This is due to lack of measuring parasite clearance times in response to drug treatment, a gold standard used to track artemisinin resistance (AR), in the Chittagong Hill Tracts (CHT), where >90% of malaria occurs in Bangladesh. Here we report delay in clinical parasite clearance half-lives > 5 h characteristic of AR, in Bandarban, a south-eastern rural, CHT district with escalating malaria and bordering Myanmar. Thirty-one and 68 malaria patients respectively presented in the clinic in 2018 and 2019, and this increase well correlated to the district-level malaria surge and rise in rainfall, humidity and temperature. A total of 27 patients with uncomplicated *Plasmodium falciparum* malaria mono-infection, after administration of an artemisinin combination therapy (ACT) showed median (range) parasite clearance half-life and time of 5.6 (1.5 – 9.6) and 24 (12–48) hours (h) respectively. The frequency distribution of parasite clearance half-life and time was bimodal, with a slower parasite clearance of 8 h in 20% of the participants. There was however, no detectable parasitemia 72 h after initiating ACT. Half-life clearance of > 5h, respectively seen in 35% and 40% of participants in 2018 and 2019, lacked in correlation to initial parasitemia, blood count parameters or resistance mutations of *PfKelch13* (K13, the major parasite marker of AR). Culture adapted strains await assessment of *in vitro* resistance and new parasite determinants of AR.

Introduction.

Malaria has taken a staggering historical toll on human health. However, in the 21st century many areas of the world are striving for elimination and eradication. From 2010-2018 malaria cases declined globally¹. Fast acting ACTs reduced levels of infection and death due to *Plasmodium falciparum*, the most virulent of human malaria parasites responsible for the major burden of disease. Yet substantial global levels of malaria remain. Over 400,000 deaths and 228 million world-wide cases of malaria occurred in 2018¹. Global malaria levels failed to decrease in 2019². Malaria elimination in Bangladesh (where 17.5 million people live at risk for infection) made strong progress from 2010 to 2018 reducing malaria cases by 81% (<http://www.nmcp.gov.bd>). Over 90% of malaria cases occur in the CHTs in three districts, Khagrachhari, Rangamati and Bandarban that border Myanmar (See Fig. 1A).

Drugs are the mainstay of treating and reducing blood stages of infection that are responsible for all the symptoms and pathologies of malaria. Resistance to drugs therefore threatens malaria control. Resistance to chloroquine arose in SEA, spread through South Asia with devastating effects for malaria morbidity/mortality in Africa 30 years ago³. More recent spread of resistance to front line artemisinins throughout SEA and Myanmar has led to concern that there may be spread to Bangladesh which in turn may lie in the path of global dissemination of resistance^{4 5 6}. AR may also arise independently^{7 8}, suggesting multiple ways that Bangladesh parasites may become refractory to these frontline drugs for which we still have no replacements.

Resistance to artemisinins was first reported in clinical studies as a delay in clearance of early blood stage (or 'ring' stage) infection from patient circulation, in response to drug treatment^{9 10}. Subsequent studies established K13 as a molecular and major, causal marker of AR in *P. falciparum* malaria^{11 12}. Studies in SEA have established strong association between polymorphisms in the β -propeller domain of K13 and delayed clearance of parasites in circulation¹³. Polymorphisms in K13 and additional genes associated

with resistance have been characterized by the laboratory-based ring stage survival assay (RSA¹⁴), an *in vitro* correlate of *in vivo* resistance. This laboratory assay is important to prove that mutations in candidate genes when engineered into sensitive parasites in local genetic or laboratory strains are causative for resistance^{15 16} as well as strains where resistance is mediated by unknown determinants¹⁷. Nonetheless, the gold standard of clinical AR remains *in vivo* delayed clearance.

Detection of mutations in K13 (as well as other drug resistance markers) by application of PCR based technologies to infected blood from patients is well established and widely utilized in Bangladesh^{18,19}. However, measurements of *in vivo* delayed parasite clearance in the CHTs has not been done. A major challenge is that CHTs are remote and rural (Fig. 1A). Here we present the first report of successful adaptation and establishment of the clinical assay of delayed *P. falciparum* clearance at a district level hospital in the CHTs. We also established *in vitro* cultures of Bangladesh strains isolated from the CHTs. Data collected over 2018-2019 revealed launching these capacities to fill critical gaps in monitoring AR in the CHTs and hematological parameters, in context of sharp escalation of malaria associated with climactic factors.

Materials and Methods

Site selection to support study design. This is an ongoing prospective study for assessing *in vivo* parasite clearance to determine presence of clinical AR and its quantitative correlation with parasitemia, comprehensive blood count parameters, AR molecular markers as well as laboratory adaptation of patient isolates to conduct further *in vitro* and genetic studies of *P. falciparum* parasite populations in Bandarban. In 2018, we established clinical capacity to measure *in vivo* AR in Bandarban Sadar Hospital. The site was chosen because it is the only hospital in the CHTs where it is possible to undertake a protocol for *in vivo* delayed *P. falciparum* clearance as recommended by the Worldwide Antimalarial Resistance Network (WWARN)^{20,21}. For this protocol WWARN recommends obtaining multiple patient blood draws over a 72

h period. The procedure therefore necessitates clinical facilities for in-patient stay for consecutive nights. This is only available at Bandarban Sadar Hospital because it is the sole district level hospital in Bandarban District that has all the required facilities.

To reach our target number of isolates for screening of K13 polymorphisms (see sample size calculation), in 2019 we added collection of parasite isolates at Alikadam Upazilla Health Complex because of its higher annual parasitological index (API; Alikadam 21.84 in 2018, 32.13 in 2019; Bandarban- 0.83 in 2018; 1.6 in 2019).

Sample size calculation: The absence of substantial information on K13 polymorphisms and no data for *in vivo* clearance in Bangladesh, limited local information on which to base power calculations. We therefore used findings from neighboring Myanmar, that reports 20% prevalence rate of the F446I mutation²². We assumed the same prevalence in Bandarban for all point mutations in the propeller domain of the K13 gene with 10% detected difference (precision), 80% power and 95% level of significance. On this basis, we calculated a sample size of 126 which was also expected to be within clinical capacity and existing information on patient enrollment.

Patient screening: Patients were screened when presented with positive malaria diagnosis by microscopy and/or RDT. The inclusion criteria were *P. falciparum* mono-infection, axillary temperature $\geq 37.5^{\circ}\text{C}$ or history of fever during the past 24 h, ability and willingness to comply with the study protocol for the duration of the study, informed consent from the patient or a parent or guardian in the case of children and minimum age of children ≥ 1 year. The exclusion criteria included severe malaria according to the WHO definition¹¹ i.e. organ dysfunction, multiple convulsions, impaired consciousness. The exclusion criteria additionally included severe malnutrition, anemia (Hb $< 8\text{g/dL}$), self-administered antimalarial or antibiotics before enrollment or pregnancy.

Parasite clearance study procedure: Prior to administration of the first dose of Artemether-lumefantrine combination therapy (ACT) called KOMEFAN 140 (Mylan Laboratories Ltd., India), the initial parasite density and speciation was counted against 200 white blood cells (WBC; thick smear) or 2000 RBC (thin smear with duplicate slides stained with Giemsa (Merck, Germany). The smears were counted in duplicates by two independent microscopists and then averaged. Parasite density/ml was calculated by dividing the number of asexual parasites by the number of WBC counted (200) and multiplying by an assumed WBC count of 8,000/ μ l in thick film (or thin film, if the thick film was >250 parasites/50 WBC). Smears were considered negative when no asexual parasites were found after counting 200 WBC.

The admitted IPD (Indoor Patient Department) patients were treated by the hospital staff as per the protocol of the National Malaria Elimination Program. Briefly, one to four tablets (depending on patient's body weight) of KOMEFAN 140 (containing 20 mg Artemether and 120 mg Lumefantrine), was administered at each of the following six time points 0 h, 8 h, 24 h, 36 h, 48 h, 60 h 72h. Blood draws were planned at 6, 12, 24, 36 and 48 h post first drug administration²⁰. Due to logistical difficulties, at the outset, the 12 and 24 h time points were respectively replaced by 18 and 36 h. However, some patients showed rapid reduction of parasites in the 12 h interval between 6 h and 18 h which limited fitting to curve. For this reason, the first four blood draws were undertaken every 6 h after administration of the first ACT (namely, 6, 12, 18, 24 h), followed by a time point every 12 h at 36, 48, 60, 72 h.

Patients were confirmed to be free of parasites and fever for at least one day and up to 72 h prior to being released from the clinic. Smears were considered negative when no asexual parasites were found after counting 200 WBC or 2000 RBCs. Patients were subsequently followed up for fever, pulse and blood pressure and malarial infection (by RDT and slides) up to 30 days at home weekly on day 9, 16, 23 and 30. No abnormalities were found. The study had no influence on the treatment decisions made by the hospital physicians.

Analyses of parasite clearance data. Parasite clearance times (PCTs) were determined for each patient using the WWARN parasite clearance estimator (PCE) tool²¹. The parasite clearance half-life was determined by plotting serial parasite counts on the parasite clearance estimator tool by WWARN^{20,21}. The following parameters were defined: Clearance rate constant: the fraction by which parasite count falls per unit time. Slope half-life: Estimated time in hours it takes for the parasitaemia to decrease by half (50%), independent of initial parasite density. PC_{50, 90, 95 and 99}: Estimated time in hours for parasitaemia to be reduced by 50%, 90%, 95% and 99% of its initial value (initial parasite density) respectively. All definitions above follow WWARN methodology for calculating parasite clearance^{20,21}.

Blood cell assessment: Sysmex XP-300 Haematology Analyser (Sysmex Corporation, Kobe, Japan) was used to provide a full blood cell count including differential white blood cell counts, prior to administration of the ACT.

Culture adaptation of patient isolates: 10ml venous blood was drawn before administering ACT from adults (≥18 years of age) and 7ml from adolescents (ages 11-17) using K₂EDTA vacutainers (7.2 mg; 4.0 mL; Becton Dickinson, Erem-bodegem, Belgium). Most of the bulk amount of parasitized venous blood committed to culture adaptation was washed, resuspended to 4% hematocrit with freshly washed uninfected red blood cells in 5ml RPMI 1640 medium containing L-glutamine, 50 mg/liter hypoxanthine, 25mM HEPES, 2g/liter glucose, 20 µg/ml gentamicin, 0.225% NaHCO₃ and 15% human pooled plasma with 0.5% Albumax. The suspension was introduced into a culture flask placed in a candle jar (gas conditions: 5% CO₂, 5–10% O₂ and 85–90% N₂) which in turn was placed in an incubator at 37° C. Culture media was changed and thin smears with Giemsa were made every day. When the parasitemia reached 2% rings, the cultures were frozen for storage. The times to reach 2% was noted. An adaptation was considered unsuccessful if no parasites emerged upto 60 days.

DNA extraction: Genomic DNA was extracted from 200 µl whole blood using the QiaAmp blood mini kit (QIAGEN, Inc., Germany) according to the manufacturer's instructions. 500ul of patient whole blood was cryopreserved for future experiments.

Species confirmation by genotyping: Malaria species was confirmed by using nested PCR method following previously published method with minor modifications ¹⁹.

K13 propeller domain sequence: The sequence of the propeller domain of *kelch13* gene was amplified by nested PCR adapted from previously described procedures^{11 19} An 849 bp product was amplified by ExoSAP-IT (Affymetrix). Amplified products were sequenced using the Sanger sequencing method on an ABI 3500 Genetic Analyzer (Life Technologies, USA). Sequencing primers: K13_N1_F: 5'- GCC AAG CTG CCA TTC ATT TG – 3', K13_N1_R: 5' – GCC TTG TTG AAA GAA GCA GA -3'. Both forward and reverse strands were aligned against *P. falciparum* 3D7 strain (PF3D7_1343700, PlasmoDB Release 46) using CLC sequence Viewer 8 (QIAGEN Aarhus A/S).

Weather data: Weather data for 2018 and 2019 was obtained from Soil Resource Development Institute (SDRI), Bandarban, Bangladesh.

Ethical approval: The study was approved by the Ethical Review Committee of icddr,b (Protocol # PR-17078) and the Institutional Review Board of the University of Notre Dame (Protocol # 17-10-4146).

Maps. ArcGIS 10.4.1 (ESRI Inc., Redlands, CA) was used to generate malaria incidence map for 2019.

Statistical analysis: Associations between two variables were assessed using Spearman correlation and Mann-Whitney analysis. All statistical analyses were performed using GraphPad Prism 7 (GraphPad Software, La Jolla, CA).

Results.

200

201 **Overall Clinical Presentation Profiles.** As indicated earlier, *in vivo* parasite clearance studies in
 202 Bandarban Sadar Hospital were undertaken over two years from 2018-2019 (Fig. 1). In 2018, of 31
 203 patients who presented with malaria symptoms, 17 were excluded because they were either infected or
 204 co-infected with *P. vivax*, showed severe malaria, were anemic or pregnant, had recent prior exposure to
 205 antimalarials, refused to consent or were rapid diagnostic test negative despite having malaria symptoms
 206 (also summarized in Fig. 1B). Of the 14 with *P. falciparum* mono-infections, 9 were enrolled in PCT
 207 studies. The remaining 5 showed initial parasitemias below 1000 parasites/ μ l, the threshold level for
 208 inclusion in PCT measurements. However, all 14 were subjected to K13 marker analyses and
 209 hematological assessments. In 2019, of 68 patients who presented with malaria symptoms, 27 met
 210 inclusion criteria of *P. falciparum* mono-infection without additional factors. 18 who showed initial
 211 parasitemia $\geq$ 1000 parasites/ μ l were enrolled in PCT studies (but all 27 were included in K13 and
 212 hematological analyses).

213

214 Together the data in Fig. 1 suggested that although *P. falciparum* infections were dominant, only about a
 215 third could be utilized for PCT studies due to other complications of presentations or insufficient threshold
 216 parasitemia. One unexpected observation was that the number of malaria patients presenting at the clinic
 217 increased by ~2 fold from 2018 to 2019 (Fig. 1B). We took this in context that many levels of vector borne
 218 diseases like malaria can be affected by climate and Bangladesh is known to be vulnerable to climate
 219 change. As shown in Fig. 2A, monthly presentation of malaria patients in the clinic, closely corresponded
 220 with the monthly parasite incidence levels in the district (Spearman correlation coefficient, $\rho = 0.8804$, p
 221 < 0.0001) which in turn showed significant correlation to rainfall (Spearman co-efficient, $\rho = 0.73$, $p <$
 222 0.0001 (Figure 2B), humidity (Spearman co-efficient, $\rho = 0.91$, $p < 0.0001$) and minimum temperature
 223 (Spearman co-efficient, $\rho = 0.72$, $p = 0.0001$) seen in Bandarban (Fig. 2C). This strongly suggested that
 224 the two-fold increase seen in presenting patients in 2019 was due to higher levels of malaria in the district
 225 rather than other determinants affecting access and care.

226

227 Participants enrolled in PCT studies were young adults with 67% males (Table 1). At time of presentation,
228 all but one had fever ($\geq 37.5^{\circ}\text{C}$) and none were significantly anemic (hemoglobin < 9 g/dl for females and
229 10 g/dl for males) (Table 1, Supplementary Table 1 and Supporting Information SI). All participants
230 tolerated and complied with study procedures. No serious adverse events were reported. Mild to moderate
231 adverse events of headache, body aches, nausea, vomiting, fever or chill were observed and recorded
232 for each participant. They were related to acute malaria illness and resolved within 72 h /3 days.
233 Participants did not receive acetaminophen or other anti-pyretics after the first dose of the ACT KOMEFAN
234 140.

235

236 **Clinical Outcomes and Parasite Clearance.** Enrollment parasite densities were moderate in each year
237 (Table 1). Over two years, the geometric mean was 20020/ μl ; 95% confidence interval 9,840 – 116,875
238 / μl . The median time to fever clearance was 24 with a range of (24 to 48 h; not shown). The aggregate
239 of all data points were included in measurement of parasite clearance time independent of initial
240 parasitemia (Fig. 3A; Table 2). Over the 27 patients, the median (range) parasite clearance half-life and
241 time was 5.57 (1.5 – 9.6) and 24 (12–48) h, respectively. The median (range) parasite clearance half-life
242 of patients enrolled in 2018 and 2019 was 3.1 (1.5 – 4.8) h and 6.98 (2.86 – 9.6) h respectively (Table 2;
243 Supplemental Fig. S2A and S2B). Parasite clearance estimation profiles of individual patients with 50%
244 clearance rates of > 5 h are provided in Supplemental figure S1. Lag-phase in parasite clearance was
245 detected in 8 out of 10 patients with delayed 50% clearance. Parasite clearance half-life based on the
246 initial value and the time required to reach 50%, 90% and 95% (PC_{50} , PC_{90} , and PC_{95}) are summarized in
247 Table 2. All parasite infections were cleared by 72 h /3 days after starting treatment (Fig. 3B-C).

248

249 Since the number of participants were different in 2018 and 2019, we examined the proportion of
250 participants as a function of the time in hours to a 'slide-negative' state to confirm that clearance was
251 achieved by 60 h (Fig. 3C; Supplementary Fig. S2 C-D). While most patients in 2018 and 2019 reported

complete parasite clearance within 48 h in 2018 and 2019; one patient reported 54h to clear all parasites, the longest time recorded for complete parasite clearance in this study (Supplemental Fig. S2 E- H). Histograms of number of participants and their clearance constant rate/hour (Fig 3D-E) suggested the highest number of participants (34%) having a clearance constant rate of 0.30/h, followed by 11% of participants having a clearance constant rate of 0.45/h, the second highest percentage of participants. Analyses of the proportion of parasites as a function of PC₅₀ also supported a bimodal distribution (Fig. 3F-G) This included the expected fast clearing parasites that reach median 50% density by 3 (2.0-4.0) h, but in addition, approximately 20% of parasites showed a slower median clearance half-life of 8 (6-10) h. This was more marked in 2019 compared to 2018. The proportion of participants per year with PCT >0.5 increased from ~ 34% to 40% from 2018 to 2019, with 38% of patients having median 50% parasite clearance of 8.4 (7.6 – 10.2) h in 2019. Together these data suggest that *in vivo* delayed clearing *P. falciparum* was reliably detected in two consecutive years, 2018 and 2019. Moreover, although the number of *P. falciparum* infection levels increased ~2 fold, the fraction of slow clearing in 2019 was comparable to that in 2018. Nonetheless, all infections were cured, indicating that there was no failure of ACT KOMEFAN.

We subsequently undertook regression analyses to understand parasite and host factors that may influence parasite clearance. As shown in Fig. 4, there was no major association between PC₅₀ and potential modifiers including age, gender and initial parasite density in either 2018 or 2019. Additionally, regression analyses failed to yield high-confidence associations between PC₅₀ and initial mean corpuscular volume (MCV) mean corpuscular hemoglobin concentration (MCHC), mean corpuscular hemoglobin (MCH) white blood cells- total count (WBC/TC), mixed cell count (MXD)-monocytes–basophils–eosinophils and platelets (Fig. 5). Regression and correlation analyses, median values and range for all parameters are respectively shown in Fig. 5, and Table 3. Regression and correlation analyses between initial parasite density and hematological parameters also failed to show high-confidence associations (Supplemental Fig. S3). Together the data in Figs. 4, 5, Supplemental Fig. S3

and Table 3, suggest that initial parasitemia and blood count parameters did not make substantial contribution to *in vivo* delayed clearance phenotype. Patient hematological readouts are provided in Supplementary Table 2 and Supporting Information (SI)

K13 polymorphisms. Since comprehensive assessment of K13 polymorphisms in Bangladesh is not yet available, we used polymorphisms in neighboring Myanmar as the best guide for power calculations. F446I has been reported at 20% prevalence in Myanmar²², based on which we projected requirement for collecting 126 isolates for our studies. In 2018, low numbers of patients were enrolled in Bandarban Sadar due to low levels of malaria in the area. Because of this in 2019, we added collection of parasites in Alikadam Upazilla Health Complex where the API was more than ten-fold higher than in Bandarban Sadar.

As summarized in Fig. 6 A-B, samples were collected from a total of 86 patients with acute *P. falciparum* mono-infection without severe manifestation were enrolled in Alikadam. Participants ranged from pediatric to young adults. 63% and 75% were males in 2019 and 2020 respectively. Parasite densities were moderate (2018 geometric mean, 22,460/ μ l; 95% confidence interval 4,860 – 35,850; 2019 geometric mean, 45,000/ μ l; 95% confidence interval 4480-145,000) and patients were not anemic (Hb<9 g/dl). Since K13 polymorphisms associated with AR are invariably associated with β -propeller domain, we restricted analyses to this region. As shown in Fig. 6C, there were no polymorphisms identified in Bandarban Sadar. One polymorphism K13A578S was detected in Alikadam. Prior studies have reported K13A578S which is known to be a sensitive mutation, in the CHT¹⁸. Together these findings suggest that *in vivo* delayed clearance cannot be explained by resistance mutations in the β -propeller domain of K13.

Culture adaptation. Studies in SEA established strong association between polymorphisms in the β propeller domain of K13 and delayed clearance of parasites in circulation. However, polymorphisms in

additional genes have also been associated and shown to be causal for resistance as determined in the laboratory-based ring stage survival assay (RSA)^{14 16 15}. As summarized in Fig 7A, we culture adapted 7 of 9 isolates obtained in 2018 and one of 18 in 2019. The range of initial parasitemia varied from 0.06% to 3.9%. Nonetheless 2% parasitemia was achieved within 9-12 days. In 2018, >75% of isolates were successfully adapted. However, in 2019, only one isolate (5%) could be adapted. The reasons for this variability in culture adaptation remain unclear and need to be explored in further studies.

Discussion

The goal of Bangladesh's national strategic plan for malaria 2017–2021 is to eliminate the disease by 2030²³. A key component of the plan is to prevent emergence of *P. falciparum* strains resistant to artemisinins. This needs to be accomplished in addition to interrupting local transmission, and preventing reestablishment of infection. Measuring *in vivo* delayed clearance of parasites in response to ACT treatment in malaria patients and establishment of culture-adapted Bangladesh strains to determine parasite-intrinsic resistance, are both critically important to guide strategies and interventions to achieve and sustain elimination. It will be imperative to understand whether one or both expand over time. Hence this study fills an important gap in knowledge and approaches to identifying emergence of AR in the CHTs where >90% of malaria occurs in Bangladesh.

From 2018-2019 malaria had an average of 60% resurgence across Bandarban. Infections rose in the low-API sub-district of Bandarban Sadar as well as Alikadam, with high API. The increase was well correlated with climatic factors, suggesting it may be due to increasing local transmission which is a malaria control priority that must be considered in conjunction of emerging AR²⁴. Previous studies have reported on analyses of K13 polymorphisms in Bangladesh¹⁸. A single study¹³ reported median (range) parasite clearance half-life of 2.5 (0.7 to 5.4) in Ramu in Cox's Bazar (where malaria incidence is low) but not in the Hill Tracts. Nor did they establish culture adaptation of Bangladesh strains, which is important, since Bangladesh strains appear to be genetically separable from SEA and Indian strains²⁵ and AR is

known to be *P. falciparum* strain dependent. In our study, the clinical presentation of malaria in the Bandarban Sadar Hospital was representative of overall malaria levels and their escalation in the district, suggesting the findings have implications for the entire district and possibly the CHT. We report presentations of *P. vivax*, co-infection of *P. vivax* and *P. falciparum* as well as *P. falciparum*-induced severe disease, with substantial increase in severe disease in 2019. Consistent with prior reports ²⁶ *P. falciparum* caused ~80-90% of infections in Bandarban. However, acute, uncomplicated, mono-infection by *P. falciparum* represented 45% and 39% of patients in 2018 and 2019 respectively and only about two thirds of those had parasite densities >1000/μl.

We detected delay in 'ring' parasite clearance half-life > 5 h, a characteristic for AR in Bandarban. Rings are the parasite stage in the circulation and can be readily detected in a blood draw. 35-50% of enrolled patients showed delay in parasite clearance half-life for two consecutive years. Initial parasite densities > 1000 parasites /μl and time points taken every 6 hours for first 24 h after the administration of first ACT dose were critical to analyzing the data using the WWARN PCE tool. At the outset of the study, after the first draw at 6 h subsequent time points were spaced 12h apart in the first 24-30 h. But only 60% of these collections could be evaluated by the PCE tool. Upon correction to every 6 h, 100% of collections yielded interpretable data.

Across 27 patients, the median parasite clearance half-life was 5.6 h, but as many as a fifth showed much greater delayed clearance half-life of 8h. Nonetheless there was no evidence of drug failure either during the first 72h in the clinic or the following 30 days at home. This suggested that while there may be a delay in clearing rings, later stage parasites were effectively eliminated due to activity of the long lived partner drug and that the ACT is still effective. This is in contrast to Cambodia, Thailand and Vietnam where ACT combinations have lost efficacy ^{6,27 28}. There was no correlation between the time to 50% of the initial parasite density (PC₅₀) and initial parasitemia or blood cell counts. Notably, although platelet levels were significantly reduced relative to parasitemia (not shown) they showed no correction with PC₅₀. In the case

of initial Hb, lymphocytes and neutrophils, although the correlation coefficient was low (< 0.6), the p values were < 0.05 , suggesting there may be weak correlation to further evaluate in subsequent studies. In prior work, correlates of immunity has been inversely correlated with delayed clearance²⁹. In future studies, measuring blood cell count every six hours during the first 24 h of parasite clearance, is expected to capture data most pertinent to the window for *in vivo* parasite delayed clearance.

A single K13 polymorphism associated with sensitive parasites was detected, suggesting that the observed *in vivo* delayed parasite clearance characteristic of AR cannot be due to a resistance mutation in K13. Further K13 resistance polymorphisms in Bandarban have not expanded to the extent (~20%) reported in Myanmar. Establishment of parasites adapted for culture greatly facilitates understanding whether parasites that show delayed *in vivo* delayed clearance are also resistant *in vitro* (as measured by the RSA that evaluates ring stage resistance) laying the ground work to identify new parasite determinants of resistance. To the best of our knowledge this is the first report of culture adaptation of Bangladeshi parasites. A high level of success was achieved in 2018, when 7 out 9 isolates were successfully adapted. In 2019 only one (of 18) was culture adapted. The reasons remain unclear but one possibility is that because of the increase in malaria incidence, there were higher levels of long lived partner drugs in the circulation of the patient in 2019 and that compromised lab-adaptation. To address this issue, future studies need to include measurements of the concentration of partner drug after *in vivo* blood collection.

Since the Alikadam sub-district clinic facility lacks facilities for overnight stay, *in vivo* parasite clearance measurements were not undertaken there. But Alikadam was selected as a second site because it has a sub-district clinic (Alikadam Upazilla Health Complex, with 30 beds to monitor day patients) and its API was much higher than that of Bandarban (21.4 compared to 0.83 in 2018 and 32.13 compared to 1.60 in 2019). It is also closer to the border with Myanmar, where K13 resistance mutations have been reported. Work in Alikadam enabled rapid expansion of collection of infected blood samples for analyses of K13 polymorphisms and adapting Bangladeshi parasites into cultures. Building the requisite clinical capacity

for overnight stay and *in vivo* parasite clearance studies will render Alikadam as a superior sub-district site for *in vivo* delayed clearance studies. This will also provide a model to expand to other sub-districts in Bandarban and the CHT, to broaden the assessment clinical AR across remote rural, forested regions with low population density, that present the major frontier of malaria in Bangladesh.

Conclusions.

We have established for the first time, capacity to measure *in vivo* parasite clearance times in response to drug treatment, a gold standard used to track AR, culture adaptation of Bangladeshi parasite strains and a model to expand both clinical and laboratory studies in remote, rural areas of Bangladesh that have the greatest concentration of malaria. We report clinical parasite clearance half-life > 5 h characteristic of AR, and culture adaptation of Bangladesh strains that empowers future laboratory analyses to determine whether clinical AR in Bandarban is an intrinsic parasite property as well as underlying new parasite determinants.

Acknowledgments. This work was supported by the University of Notre Dame, Keough School for Global Affairs, Notre Dame Research and the Provost Office as well as National Institutes of Health USA, R01 HL 1330330 (KH). We are grateful to the study participants. We thank Dr. Mathew Sisk (Hesburgh Libraries, University of Notre Dame) for assisting in creating the incidence map of Bangladesh. We thank Dr. Arjen Dondorp (Mahidol Oxford Tropical Medicine Research Unit) for helpful discussions. We thank the Soil Resource Development Institute (SRDI), Bandarban for weather data. icddr,b acknowledges with gratitude the commitment of University of Notre Dame to its research efforts. icddr,b is also grateful to the Governments of Bangladesh, Canada, Sweden, and the UK for providing core/unrestricted support.

Author Contributions.

404 MKN. Conceptualization, study design, establishment and supervisor of field lab, adaptation of filed
405 strains to *in vitro* cultures curation and analyses of all data, visualization of results, drafting and editing of
406 manuscript.

407 SAS. Supervision of field lab at both the sites, in vitro culture maintenance and establishment, and data
408 curation

409 AM. Conceptualization, adaptation of field strains to *in vitro* cultures, curation and analyses of all data,
410 visualization of results, drafting and editing of manuscript.

411 MRHH. Supervision of field lab in Bandarban Sadar, data curation, in vitro culture maintenance, and
412 establishment.

413 CSP. Clinical supervision and monitoring, and data curation

414 FTJ. Diagnostic PCR, K13 sequencing, and data curation.

415 IS. Statistical analyses and support, visualization of results and data curation.

416 AS. Management information systems specialist support for database support.

417 ASK. Study site supervision and facilitation.

418 RW. Conceptualization and design of blood cell count analyses, data curation and manuscript editing.

419 NM. Conceptualization and design of blood cell count analyses, data curation and manuscript editing.

420 ASM. Study supervision and facilitation (civil surgeon of Bandarban).

421 BC. Clinical Protocol Review and Approval University of Notre Dame.

422 RH. Co-investigator, study supervision

423 WAK. Co-investigator, study supervision

424 Md S. A. Field site Principal Investigator, conceptualization and project supervision, design and
425 development of research plan, data analyses, drafting and editing of manuscript.

426 KH. Principal Investigator, overall conceptualization and project supervision, design and development of
427 research plan; curation and analyses of all data, visualization of results; drafting and editing of
428 manuscript, funding acquisition.

429

References Cited.

1. WHO. World Malaria Report 2019. <https://www.who.int/publications-detail/world-malaria-report-2019>. 2019.
2. WHO. World Malaria Report 2020. <https://www.who.int/publications/i/item/9789240015791>. 2020.
3. Mita T, Tanabe K, Kita K. Spread and evolution of Plasmodium falciparum drug resistance. *Parasitology international*. 2009;58(3):201-209.
4. Imwong M, Suwannasin K, Kunasol C, et al. The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study. *The Lancet Infectious diseases*. 2017;17(5):491-497.
5. Haldar K, Bhattacharjee S, Safeukui I. Drug resistance in Plasmodium. *Nature reviews Microbiology*. 2018;16(3):156-170.
6. Ménard D, Fidock DA. Accelerated evolution and spread of multidrug-resistant Plasmodium falciparum takes down the latest first-line antimalarial drug in southeast Asia. *The Lancet Infectious Diseases*. 2019;19(9):916-917.
7. Uwimana A, Legrand E, Stokes BH, et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. *Nature medicine*. 2020;26(10):1602-1608.
8. Mathieu LC, Cox H, Early AM, et al. Local emergence in Amazonia of Plasmodium falciparum k13 C580Y mutants associated with in vitro artemisinin resistance. *eLife*. 2020;9:e51015.
9. Noedl H, Se Y, Schaefer K, Smith BL, Socheat D, Fukuda MM. Evidence of artemisinin-resistant malaria in western Cambodia. *The New England journal of medicine*. 2008;359(24):2619-2620.
10. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J. Artemisinin resistance in Plasmodium falciparum malaria. *The New England journal of medicine*. 2009;361.
11. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N. A molecular marker of artemisinin resistant Plasmodium falciparum malaria. *Nature*. 2014;505.
12. Straimer J, Gnädig NF, Witkowski B, et al. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. *Science (New York, NY)*. 2015;347(6220):428-431.
13. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S. Spread of artemisinin resistance in Plasmodium falciparum malaria. *The New England journal of medicine*. 2014;31.
14. Witkowski B, Amaratunga C, Khim N, et al. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. *The Lancet Infectious diseases*. 2013;13.
15. Demas AR, Sharma AI, Wong W, et al. Mutations in Plasmodium falciparum actin-binding protein coronin confer reduced artemisinin susceptibility. *Proceedings of the National Academy of Sciences of the United States of America*. 2018;115(50):12799-12804.

16. Henriques G, van Schalkwyk DA, Burrow R, et al. The Mu subunit of Plasmodium falciparum clathrin-associated adaptor protein 2 modulates in vitro parasite response to artemisinin and quinine. *Antimicrob Agents Chemother*. 2015;59(5):2540-2547.
17. Mukherjee A, Bopp S, Magistrado P, et al. Artemisinin resistance without pfkelch13 mutations in Plasmodium falciparum isolates from Cambodia. *Malaria Journal*. 2017;16(1):195.
18. Mohon A, Alam MS, Bayih AG, Folefoc A, Shahinas D, Haque R. Mutations in Plasmodium falciparum K13 propeller gene from Bangladesh (2009–2013). *Malar J*. 2014;13.
19. Alam MS, Ley B, Nima MK, et al. Molecular analysis demonstrates high prevalence of chloroquine resistance but no evidence of artemisinin resistance in Plasmodium falciparum in the Chittagong Hill Tracts of Bangladesh. *Malaria Journal*. 2017;16(1):335.
20. Flegg JA, Guérin PJ, Nosten F, et al. Optimal sampling designs for estimation of Plasmodium falciparum clearance rates in patients treated with artemisinin derivatives. *Malaria Journal*. 2013;12(1):411.
21. Flegg JA, Guerin PJ, White NJ, Stepniewska K. Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. *Malar J*. 2011;10:339.
22. Tun KM, Imwong M, Lwin KM, Win AA, Hlaing TM, Hlaing T. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. *Lancet Infect Dis*. 2015;15.
23. National Malaria Elimination Program. National Strategic Plan for Malaria Elimination 2017–2021. *Directorate General of Health Services MoHaFW, editor Dhaka, Bangladesh: Directorate General of Health Services, Ministry of Health and Family Welfare*. 2017.
24. Alam MS, Al-Amin HM, Khan WA, Haque R, Nahlen BL, Lobo NF. Preliminary Report of Pyrethroid Resistance in Anopheles vagus, an Important Malaria Vector in Bangladesh. *The American journal of tropical medicine and hygiene*. 2020;103(2):810-811.
25. Kumar S, Mudeppa DG, Sharma A, et al. Distinct genomic architecture of Plasmodium falciparum populations from South Asia. *Molecular and Biochemical Parasitology*. 2016;210(1):1-4.
26. Ahmed S, Galagan S, Scobie H, et al. Malaria hotspots drive hypoendemic transmission in the Chittagong Hill Districts of Bangladesh. *PLoS One*. 2013;8(8):e69713.
27. Phuc BQ, Rasmussen C, Duong TT, et al. Treatment Failure of Dihydroartemisinin/Piperaquine for Plasmodium falciparum Malaria, Vietnam. *Emerging infectious diseases*. 2017;23(4):715-717.
28. van der Pluijm RW, Imwong M, Chau NH, et al. Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. *The Lancet Infectious diseases*. 2019;19(9):952-961.
29. Ataide R, Ashley EA, Powell R, et al. Host immunity to Plasmodium falciparum and the assessment of emerging artemisinin resistance in a multinational cohort. *Proceedings of the National Academy of Sciences of the United States of America*. 2017;114(13):3515-3520.

Main Tables

Table 1: Presenting clinical characteristics and parameters of participants enrolled in PCT studies in Bandarban District Hospital Sadar, 2018 - 2019. (See also Supplementary Table 1).

Parameters	Value Median (IQR)		
	2018	2019	Combined (2018 and 2019)
Number of patients	9	18	27
Age	29 (15 -45)	17.50 (13.75 -42.75)	24 (14 – 45)
Gender	Male 66.67%	Male 66.67%	same
Temperature at enrollment (°C)	38 (36.6 – 39.4)	37.7 (37.2- 38.3)	38.8 (37.7- 39.4)
Initial density of Plasmodium falciparum (per µL)	22280 (8760-152500)	18900 (9790-64829)	20020 (9840 – 116875)
Parasitemia (%)	0.52 (0.15-2.83)	0.34 (0.18-1.5)	0.34 (0.17 – 2.2)
Hemoglobin (g/dl)	Male: 13.75 (11.18-15.30) Female: 10.70 (9.40- 11.90)	Male: 11.55 (10.58-13.40) Female: 10.95 (9.52- 13.73)	Male: 12.20 (10.95 – 14.05) Female: 10.70 (9.5 – 12.75)

Table 2: Parasite clearance data, median (IQR) (range) of study participants in 2018 and 2019.

Parasite clearance	2018 Median (IQR) (range)	2019 Median (IQR) (range)	2018 and 2019 Median (IQR) (range)
Parasite clearance time (h) ^a	24 (15 – 24) (12 – 36)	24 (18 – 36) (12 – 48)	24 (18 – 36) (12 – 48)
Parasite clearance half-life (h) ^b	3.1 (1.52 – 3.09) (1.5 – 4.8)	6.98 (3.2 – 7.89) (2.86 – 9.6)	5.6 (2.89 – 7.38) (1.5-9.6)
PC ₅₀ (h)	3.56 (1.8-5.6) (0.015 – 7.98)	3.965 (3.21-8.26) (1.25 – 13.14)	3.56 (2.83 – 7.68) (0.015 - 13.14)
PC ₉₀ (h)	8 .42 (6.4-11.22) (5.32 – 13.75)	9.45 (8.06-13.45) (5.65 – 19.22)	9.04 (7.67 – 12.92) (5.32 - 19.22)
PC ₉₅ (h)	10.96 (8.23- 13.18) (6.74 – 17.14)	12.44 (10.16-15.85) (6.87 – 21.83)	11.83 (9.6 – 14.96) (6.74 - 21.83)
PC ₉₉ (h)	16.8 (12.5-18.64) (10.04 – 25.02)	19.16 (14.63-21.4) (9.69 – 27.92)	17.43 (14.30 – 19.74) (9.69 - 27.92)

^aFirst observed negative microscopy slide after first dose of ACT (hours)

^bEstimated time (hours) for 50% reduction in parasite density

(Parasite clearance) PC_{50, 90, 95, 99} (hours) = time for 50, 90, 95 and 99% reduction in initial parasite density

Table 3: Presenting hematological and immune cell characteristics of participants enrolled in PCT studies in Bandarban District Hospital, Sadar, 2018 -2019. (See also Supplementary Table 2).

Parameters	Value Median (IQR)		
	2018	2019	2018 and 2019
Number of participants	9	18	27
Reticulocytes (%)	0.97 (0.79-1.1)	0.9 (0.68-1.25)	0.9 (0.72 – 1.18)
Platelets x 10 ³ (per µL)	94 (40.50-144)	74 (51.75-120.8)	81 (48 – 141)
MCV (fL)	68.80 (65.25 – 81.75)	66 (60.60 – 73.30)	68.20 (61.40 – 76.50)
MCH (pg)	24.90 (22 – 28)	21.95 (19.40 – 25.05)	22.80 (20.10 – 26.20)
MCHC (g/dl)	34 (33.10 – 34.55)	33.25 (32.40 – 33.85)	33.40 (32.60 – 34.10)
WBC-TC x 10 ³ (per µL)	5.4 (4.7 -6.75)	6.45 (4.4-7.95)	5.9 (4.5 – 7.3)
Lymphocytes (%)	23.30 (12.10 -30.40)	20.30 (12.18 -37.33)	20.90 (13 – 32)
Neutrophils (%)	66.50 (52.75 – 79.85)	68.60 (54.65 – 77.75)	67.20 (56.20 – 77.90)
Monocyte, eosinophil and basophils- mixed cell count (MXD) (%)	5.3 (4.95 – 19.35)	6.15 (4.5 – 9.3)	6.1 (5 – 11.1)

Figure Legends

Figure 1. Study sites and flow chart. A. Map of Bangladesh highlighting the malaria endemic regions with two sub-maps showing the study sites Bandarban Sadar and Alikadam Upazilla. Data provided by the National Malaria Elimination Program Bangladesh (NMEP). **B.** Bandarban study flow chart.

Figure 2. Comparative analyses of malaria patients admitted in Bandarban Sadar District Hospital, total malaria incidence and associations with climate factors in Bandarban district, 2018-2019. A. Total monthly malaria cases in Bandarban Sadar Hospital (purple line) and Bandarban district (bars). Spearman co-efficient, $\rho = 0.8804$, $p < 0.0001$; **B.** Total monthly malaria cases (bars) and rainfall (red line) in district, Spearman co-efficient, $\rho = 0.73$, $p < 0.0001$; **C.** Total district monthly malaria cases and maximum average temperature distribution (grey squares), Spearman co-efficient, $\rho = -0.12$, $p = 0.58$; minimum average temperature (blue triangles), Spearman co-efficient, $\rho = 0.72$, $p = 0.0001$; average humidity (green triangles), Spearman co-efficient, $\rho = 0.91$, $p < 0.0001$. Annual parasite index (API) in Bandarban Sadar was 0.83 (population at risk, $n = 152,915$) in 2018 and 1.60 (population at risk, $n = 156,738$) in 2019.

Figure 3. Parasite clearance data, cumulative proportion of parasitemic patients and their clearance over time, clearance rate and associated 50% clearance values A. Parasite clearance curve showing linear regression of percent parasite density *in vivo* over time (hours) **B.** Cumulative proportion of parasitemic participants and their clearance over a 30 day period (follow-up on day 9, 16, 23 and 30) **C.** Cumulative proportion of parasitemic participants and their clearance over 72 hours after administration of first dose of ACT **D.** Proportion distribution of participants with time (hours) of first negative microscopy slide after administration of first dose of ACT **E.** Percentage of patients with clearance rate constant (per hour) **F.** Proportion of participants with associated PC_{50} values, samples collected in 2018 **G.** Proportion of participants with associated PC_{50} values, samples collected in 2019 **H.**

Percentage of participants with delayed *in vivo* clearance (PC_{50}) in 2018 and 2019. (See also Supplementary Figure S2).

Figure 4. Association between 50% parasite clearance (PC_{50}) and baseline parameters **A.** Age of study participants, Spearman co-efficient, $\rho = -0.026$, $p = 0.89$, $R^2 = 0.00096$ **B.** Mann-Whitney test of PC_{50} between male and female participants, $p = 0.17$ **C.** Initial parasite density, samples collected in 2018, Spearman co-efficient, $\rho = 0.63$, $p = 0.076$, $R^2 = 0.04$ **D.** Initial parasite density, samples collected in 2018, Spearman co-efficient, $\rho = 0.27$, $p = 0.28$, $R^2 = 0.017$ **E.** Initial parasite density, samples collected in 2018 and 2019, Spearman co-efficient $\rho = 0.37$, $p = 0.054$, $R^2 = 0.016$

Figure 5. Association between 50% parasite clearance (PC_{50}) and hematological parameters **A.** Hemoglobin % (g/dL), Spearman co-efficient, $\rho = 0.4$, $p = 0.04$, $R^2 = 0.08$ **B.** Platelets (μ l), Spearman co-efficient, $\rho = -0.13$, $p = 0.52$, $R^2 = 0.02$ **C.** Mean corpuscular volume (MCV) (fl), Spearman co-efficient, $\rho = 0.03$, $p = 0.8$, $R^2 = 0.005$ **D.** Mean corpuscular hemoglobin MCH (pg), Spearman co-efficient, $\rho = -0.015$, $p = 0.08$, $R^2 = 0.03$ **E.** Mean corpuscular hemoglobin concentration MCHC (g/dL), Spearman co-efficient, $\rho = -0.19$, $p = 0.3$, $R^2 = 0.05$ **F.** White blood cells- total count (WBC/TC) (μ l), Spearman co-efficient, $\rho = 0.37$, $p = 0.05$, $R^2 = 0.2$ **G.** Lymphocytes (%), Spearman co-efficient, $\rho = 0.38$, $p = 0.04$, $R^2 = 0.08$ **H.** Neutrophils (%), Spearman co-efficient, $\rho = 0.48$, $p = 0.01$, $R^2 = 0.15$ **I.** Mixed cell count (MXD)-monocytes–basophils–eosinophils (%), Spearman co-efficient, $\rho = -0.32$, $p = 0.4$, $R^2 = 0.08$

Figure 6. Study flow chart of Alikadam, baseline characteristics and *k13* polymorphism in all study sites **A.** Alikadam study flow chart. **B.** Baseline characteristics, parasite clearance and incidence parameters in participants enrolled in Alikadam Upazilla Health Complex (UHC) in 2019 and 2020. **C.** *k13* polymorphisms in Bandarban Sadar and Alikadam Upazilla.

579

580 **Figure 7. Culture adaptation A.** Flow chart of laboratory culture adaptation attempt in 2018 and 2019.

581 **B.** Isolates and their initial parasitemia and days taken to reach adaptation

582

Figures

Figure 1:

Figure 2:

Figure 3:

Figure 4:

Figure 5:

Figure 6:

Figure 7:

Supplementary Tables and Figures.

S1 Table: Participant age range, febrile status, parasite density (per μl), parasitemia (%) and hemoglobin (g/dl) at time of enrollment in the study in Bandarban District Hospital, Sadar, 2018 -2019.

S2 Table: Hematological: reticulocytes (%), platelets (per μl), mean corpuscular volume (fl), mean corpuscular hemoglobin (pg), mean corpuscular hemoglobin concentration (g/dL) and immune cell characteristics (whole blood cell total count (per μl), lymphocytes (%), neutrophils (%) and monocytes-basophils-eosinophils (%) of participants enrolled in the study in Bandarban District Hospital, Sadar, 2018 -2019.

S1 Figure: *In vivo* parasite clearance measurement in individual study participants after administration of ACT at t=0, 6, 12, 18, 24 and 36 h.

S2 Figure: Analyses of parasite clearance data in patients enrolled in 2018 and 2019.

S3 Figure: Correlation analyses between initial parasite density and hematological parameters of study participants from Bandarban District Hospital, Sadar.

Supplementary Table 1: Participant age range, febrile status, parasite density (per μl), parasitemia (%) and hemoglobin (g/dl) at time of enrollment in the study in Bandarban District Hospital, Sadar, 2018 -2019.

Patient ID	Year	Age range	Temperature at enrollment (°C)	Initial parasite density (/ μl)	Parasitemia %	Hb% (g/dL)
I-001	2018	41-45	39.4476	2360	0.062433862	9.4
I-002	2018	16-20	39.4476	165000	2.777777778	15.6
I-003	2018	41-45	39.4476	22800	0.581632653	10.7
I-004	2018	41-45	37.66968	3700	0.05958132	13
I-005	2018	missing data	40.0032	15140	0.293980583	14.5
O-006	2018	26-30	36.00288	8600	0.122857143	17.7
O-007	2018	41-45	35.5584	17760	0.311578947	13.8
I-008	2018	26-30	missing data	140000	2.874743326	11.1
O-009	2018	21-25	38.3364	3920	0.062420382	13.7
I-010	2018	11-15	37.2252	13820	0.2276771	11.9
I-011	2018	21-25	36.6696	207500	3.959923664	15.2
O-012	2018	31-35	38.892	31840	0.677446809	11.6
I-013	2018	6-10	37.7808	25200	0.516393443	11.2
O-014	2018	26-30	39.4476	256250	5.187246964	13.3
O-015	2019	21- 25	38.892	4480	0.091242363	10.8
I-016	2019	11-15	40.0032	20660	0.290985915	13.9
I-017	2019	11-15	39.4476	187500	3.043831169	13.6
I-018	2019	16-20	37.66968	195000	3.140096618	12.5
I-019	2019	11-15	38.3364	15920	0.283778966	11.2
I-020	2019	26-30	37.7808	228750	3.300865801	16.4
I-021	2019	6-10	37.44744	37160	0.862180974	9.6
O-022	2019	16-20	38.892	6980	0.125765766	12.2
O-023	2019	21-25	38.892	2500	0.03671072	14.8
O-024	2019	16-20	38.3364	14840	0.230077519	15.1
I-025	2019	56-60	37.2252	1220	0.019967267	11.9
I-026	2019	56-60	38.3364	20020	0.538172043	9.6
I-027	2019	16-20	37.7808	2940	0.048756219	10.3
O-028	2019	41-45	37.66968	46100	0.80877193	10.7
I-029	2019	26-30	38.3364	40940	1.279375	10.1
I-030	2019	11-15	40.0032	116875	2.226190476	12.5
I-031	2019	11-15	38.3364	7900	0.173626374	11.8
O-032	2019	36-40	38.3364	8480	0.185152838	12.5
I-033	2019	16-20	38.892	9840	0.162376238	11
O-034	2019	0-5	40.5588	7740	0.142018349	10.1
I-035	2019	16-20	38.892	13320	0.343298969	9.3
I-036	2019	66-70	40.0032	9640	0.178518519	10.8
O-037	2019	26-30	38.3364	16940	0.268888889	13.1
O-038	2019	56-60	37.7808	3480	0.056493506	15.8
I-039	2019	36-40	38.892	47480	0.907839388	13.7
I-040	2019	51-55	40.0032	10960	0.220080321	10.5
I-041	2019	26-30	38.3364	17780	0.334839925	14.1

627

628

Supplementary Table S2: Hematological: reticulocytes (%), platelets (per μL), mean corpuscular volume (fl), mean corpuscular hemoglobin (pg), mean corpuscular hemoglobin concentration (g/dL) and immune cell characteristics (whole blood cell total count (per μL), lymphocytes (%), neutrophils (%) and monocytes-basophils-eosinophils (%) of participants enrolled in the study in Bandarban District Hospital, Sadar, 2018 -2019.

Patient ID	Year	Reticulocytes (%)	Platelets $\times 10^3$ (μL)	MCV (fl)	MCH (pg)	MCHC (g/dL)	WBC/TC $\times 10^3$ (μL)	Lymphocytes (%)	Neutrophils (%)	MXD (%)
I-001	2018	-	74	68.8	24.9	36.2	5.9	36.6	58.3	5.1
I-002	2018	-	142	80	26.3	32.8	6.8	8.5	74.9	16.6
I-003	2018	0.9	94	78.8	27.3	34.6	7.8	8.4	86.7	4.9
I-004	2018	-	121	62.3	21.2	34	6.7	28.2	66.5	5.3
I-005	2018	1.03	37	83.5	28.7	34.4	2.7	16.1	78.9	5
O-006	2018	0.84	84	75.4	26	34.5	7.5	32.2	48.8	19
O-007	2018	0.79	165	75.4	26	34.5	5.6	32.2	48.8	19
I-008	2018	1.03	146	68.2	22.8	33.4	5.1	30.7	47.2	22.1
O-009	2018	0.9	86	72.1	21.8	30.2	8	19.8	67	13.2
I-010	2018	1.3	213	60.1	19.6	32.6	4.3	30.1	38.4	31.5
I-011	2018	0.88	41	84	29	34.5	5.2	15.7	80.8	3.5
O-012	2018	0.68	46	73.4	24.7	33.6	4.8	47.2	37.5	15.3
I-013	2018	0.52	40	68.6	23	33.4	5.4	23.3	63.9	12.8
O-014	2018	0.72	29	79.8	26.9	33.8	2.9	9.7	83.6	6.7
O-015	2019	0.8	126	65.8	21.4	32.5	5.3	22.9	65	12.1
I-016	2019	1	114	60.3	13.6	32.5	12.1	9.7	85.3	5
I-017	2019	0.6	54	66.2	22.1	33.3	3.7	20.9	70.8	8.3
I-018	2019	0.4	161	61.4	20.5	33.4	7.2	18	0	0
I-019	2019	1.6	67	62.7	20.1	32.1	6.5	14.3	75.8	9.9
I-020	2019	0.8	48	68.5	22.8	33.3	9.5	9.1	85.4	5.5
I-021	2019	0.8	62	72.9	24.8	34.1	4.1	38.3	56.2	5.5
O-022	2019	0.5	102	69	22	31.9	4.2	23.3	55	21.7
O-023	2019	0.6	181	67.8	21.7	32	9.4	14.7	79.3	6
O-024	2019	1	193	71.1	23.3	32.8	5.8	12.5	79.9	7.6
I-025	2019	0.8	430	59.7	19.5	32.6	6.4	18.6	74	7.4
I-026	2019	1.8	21	74.5	25.8	34.7	5.2	45.4	48.4	6.2
I-027	2019	0.6	86	55.1	17.1	31	7.3	57.5	31.4	11.1
O-028	2019	0.5	120	54.8	17.5	31.9	7.4	42	55	3
I-029	2019	0.7	110	66.1	22	33.2	4.5	47	50	3
I-030	2019	1.40	81	65.9	21.9	33.2	8.4	13	77.9	9.1
I-031	2019	0.90	144	82.8	27.1	32.8	7.1	27	70	3
O-032	2019	1.10	121	79.7	27.3	34.2	4.8	34.4	53.7	11.9
I-033	2019	1.40	141	57	18	32	7.8	32	65	3
O-034	2019	1.20	476	59.8	18.5	31	14.3	15.7	77.7	6.6
I-035	2019	1.10	63	70.9	24	33.8	4.9	31.5	62.4	6.1
I-036	2019	0.60	104	60.7	19.1	31.4	8.9	6.4	85.4	8.2
O-037	2019	0.80	51	61.3	20.8	33.9	6.4	38	62	0
O-038	2019	1.30	74	80	25.6	32	5.8	47	52	1
I-039	2019	0.90	22	76.5	26.2	34.3	4.1	37	58	5
I-040	2019	1.20	10.5	63.1	21.3	33.8	2.2	19.7	67.2	13.1
I-041	2019	0.90	53	78.2	26.6	34	5.2	9	77.7	13.3

629

630

Supplementary Figures

Supplementary Figure S1: *in vivo* parasite clearance measurement in individual study

participants after administration of ACT at t=0, 6, 12, 18, 24 and 36 h. At t=0, smears were made prior to drug administration. Panels A-L show individual WWARN plots of patients with the half-life parasite clearance exceeding 5h. Green circle: projected zero parasitemia set at log 4 to fit Tobit regression model (Flegg et al. 2011). Grey circle: Indicating a measure in lag phase, which in panel A, is shown by the red line.

Supplementary Figure S2: Analyses of parasite clearance data in patients enrolled in 2018 and 2019. Linear regression analyses of parasite clearance times and percent parasite density *in vivo* over time (h), **A.** 2018 and **B.** 2019. Cumulative proportion of parasitemic participants and timing of their clearance of parasites over a 30 day period (follow-up on day 9, 16, 23 and 30) **C.** 2018 and **D.** 2019. Cumulative proportion of parasitemic participants and timing of their clearance of parasites over 72 h after administration of first dose of ACT, **E.** 2018 **F.** 2019. **G-H.** Proportion of participants versus time (h) for first negative microscopy slide after administration of first dose of ACT in **G.** 2018 and **H.** 2019

Supplementary Figure S3: Correlation analyses between initial parasite density and hematological parameters of study participants from Bandarban District Hospital, Sadar.

Linear regression and correlation analyses between initial parasite density (parasites/ μ l) and **A.** Platelets, Spearman co-efficient, $\rho = -0.35$, $p = 0.02$, $R^2 = 0.04$. **B.** Mean corpuscular volume (MCV), Spearman co-efficient, $\rho = 0.2$, $p = 0.2$, $R^2 = 0.036$. **C.** Mean corpuscular hemoglobin (MCH), Spearman co-efficient, $\rho = 0.3$, $p = 0.1$, $R^2 = 0.04$. **D.** Mean corpuscular hemoglobin concentration (MCHC), Spearman co-efficient, $\rho = 0.3$, $p = 0.04$, $R^2 = 0.03$. **E.** White blood cell-total count (WBC/TC), Spearman co-efficient, $\rho = -0.2$, $p = 0.17$, $R^2 = \text{no fit}$. **F.** Lymphocytes, Spearman co-efficient, $\rho = -0.2$, $p = 0.2$, $R^2 = 0.11$. **G.** Neutrophils, Spearman co-efficient, $\rho = 0.17$, $p = 0.3$, $R^2 = 0.1$. **H.** Mixed cell count (MXD)-monocyte-basophil-eosinophil, Spearman co-efficient, $\rho = -0.03$, $p = 0.8$, $R^2 = 0.008$